Attention-Deficit-Hyperactivity Disorder and Reward Deficiency Syndrome
Date
2008
DOI
Authors
Blum, Kenneth
Chen, Amanda Lih-Chuan
Braverman, Eric R.
Comings, David E.
Chen, Thomas J.H.
Arcuri, Vanessa
Blum, Seth H.
Downs, Bernard W.
Waite, Roger L.
Notaro, Alison
Version
OA Version
Citation
Blum, Kenneth, Amanda Lih-Chuan Chen, Eric R Braverman, David E Comings, Thomas JH Chen, Vanessa Arcuri, Seth H Blum, Bernard W Downs, Roger L Waite, Alison Notaro, Joel Lubar, Lonna Williams, Thomas J Prihoda, Tomas Palomo, Marlene Oscar-Berman. "Attention-deficit-hyperactivity disorder and reward deficiency syndrome" Neuropsychiatric Disease and Treatment 4(5): 893-918. (2008)
Abstract
Molecular genetic studies have identified several genes that may mediate susceptibility to attention deficit hyperactivity disorder (ADHD). A consensus of the literature suggests that when there is a dysfunction in the "brain reward cascade," especially in the dopamine system, causing a low or hypo-dopaminergic trait, the brain may require dopamine for individuals to avoid unpleasant feelings. This high-risk genetic trait leads to multiple drug-seeking behaviors, because the drugs activate release of dopamine, which can diminish abnormal cravings. Moreover, this genetic trait is due in part to a form of a gene (DRD2 A1 allele) that prevents the expression of the normal laying down of dopamine receptors in brain reward sites. This gene, and others involved in neurophysiological processing of specific neurotransmitters, have been associated with deficient functions and predispose individuals to have a high risk for addictive, impulsive, and compulsive behavioral propensities. It has been proposed that genetic variants of dopaminergic genes and other "reward genes" are important common determinants of reward deficiency syndrome (RDS), which we hypothesize includes ADHD as a behavioral subtype. We further hypothesize that early diagnosis through genetic polymorphic identification in combination with DNA-based customized nutraceutical administration to young children may attenuate behavioral symptoms associated with ADHD. Moreover, it is concluded that dopamine and serotonin releasers might be useful therapeutic adjuncts for the treatment of other RDS behavioral subtypes, including addictions.